Statistiche di base
| CIK | 1816431 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Quantum-Si incorporated
SEC Filings (Chronological Order)
Questa pagina fornisce un elenco completo e cronologico dei depositi SEC, esclusi i documenti di proprietà che forniamo altrove.
| May 22, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM SD Specialized Disclosure Report QUANTUM-SI INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-39486 85-1388175 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.) 29 Business Park Drive, Branford, Connecticut 06405 (Ad |
|
| May 15, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2026 QUANTUM-SI INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-39486 85-1388175 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 7, 2026 |
Exhibit 99.1 Quantum-Si Reports First Quarter 2026 Financial Results and Highlights ProteusTM Development Milestones Successful sequencing on integrated Proteus instruments and continued progress toward amino acid coverage and overall launch capabilities BRANFORD, Conn. - (BUSINESS WIRE) - May 7, 2026 - Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics tech |
|
| May 7, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39486 QUANTUM-S |
|
| May 7, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2026 QUANTUM-SI INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-39486 85-1388175 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 7, 2026 |
Use of Non-GAAP Financial Measures Exhibit 99.2 Use of Non-GAAP Financial Measures In addition to financial results calculated in accordance with U.S. generally accepted accounting principles (“GAAP”), information containing non-GAAP financial measures for Quantum-Si Incorporated (the “Company”) was disclosed in the Company’s press release (the “Press Release”) dated May 7, 2026 announcing results for the three months ended March 3 |
|
| April 1, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy Stat |
|
| April 1, 2026 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Def |
|
| April 1, 2026 |
ANNUAL REPORT 2025 www.quantum-si.com [THIS PAGE INTENTIONALLY LEFT BLANK] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition |
|
| March 3, 2026 |
quantum-siseveranceplan AMENDED AND RESTATED QUANTUM-SI INCORPORATED EXECUTIVE SEVERANCE PLAN PLAN DOCUMENT AND SUMMARY PLAN DESCRIPTION Effective as of November 1, 2024 1. |
|
| March 3, 2026 |
quantum-sixinsidertradin QUANTUM- SI INCORPORATED INSIDER TRADING POLICY (Effective October 2025) TABLE OF CONTENTS Page I. |
|
| March 3, 2026 |
As filed with the Securities and Exchange Commission on March 3, 2026 S-8 As filed with the Securities and Exchange Commission on March 3, 2026 Registration No. |
|
| March 3, 2026 |
Use of Non-GAAP Financial Measures Exhibit 99.2 Use of Non-GAAP Financial Measures In addition to financial results calculated in accordance with U.S. generally accepted accounting principles (“GAAP”), information containing non-GAAP financial measures for Quantum-Si Incorporated (the “Company”) was disclosed in the Company’s press release (the “Press Release”) dated March 3, 2026 announcing results for the fourth quarter and full |
|
| March 3, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File Number: 001-39486 QUANTUM- |
|
| March 3, 2026 |
Table 1: Newly Registered Securities Calculation of Filing Fee Tables S-8 Quantum-Si Inc Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Class A common stock, par value $0. |
|
| March 3, 2026 |
Exhibit 99.1 Quantum-Si Reports Fourth Quarter and Full Year 2025 Financial Results Releases List Price of ProteusTM Platform Reiterates Proteus Development Program On Track for Year End 2026 Launch BRANFORD, Conn. - (BUSINESS WIRE) - March 3, 2026 - Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics technology company redefining protein analysis through sin |
|
| March 3, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2026 QUANTUM-SI INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-39486 85-1388175 (State or other jurisdiction of incorporation) (Commission F |
|
| December 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 29, 2025 QUANTUM-SI INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-39486 85-1388175 (State or other jurisdiction of incorporation) (Commissi |
|
| December 29, 2025 |
corporatepresentation122 1 Corporate Presentation Exhibit 99.1 2 Disclaimer and Other Information Forward-looking Statements This presentation includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. The actual results of the Company may differ from its expectations, estimates, and projections an |
|
| November 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 19, 2025 QUANTUM-SI INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-39486 85-1388175 (State or other jurisdiction of incorporation) (Commissi |
|
| November 20, 2025 |
investoranalystday11-19x 1 Quantum Si Investor & Analyst Day November 19, 2025 2 Investor Day Agenda 10:00–10:10 AMTackling the Complexity of the ProteomeJeff Hawkins, CEO 10:10–10:40 AM Proteus Program Update and Long-term Technology Roadmap Todd Rearick, CTO 10:40–11:05 AMThe Path to Detecting All 20 Amino AcidsJohn Vieceli, CPO 11:05–11:25 AMPost-translational Modification Analysis Solutions Br |
|
| November 5, 2025 |
bennettseparationagreeme Exhibit 10.5 October 31, 2025 Todd Bennett Re: Separation Agreement Dear Todd: The purpose of this letter agreement (this “Agreement”) is to confirm the end of your employment with Quantum-Si Incorporated (the “Company”) as of November 7, 2025 (the “Separation Date”), and to set forth the terms of your separation from Quantum-Si Incorporated (“Company”). Payment of the Sep |
|
| November 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39486 QUANT |
|
| November 5, 2025 |
Use of Non-GAAP Financial Measures Exhibit 99.2 Use of Non-GAAP Financial Measures In addition to financial results calculated in accordance with U.S. generally accepted accounting principles (“GAAP”), information containing non-GAAP financial measures for Quantum-Si Incorporated (the “Company”) was disclosed in the Company’s press release (the “Press Release”) dated November 5, 2025 announcing results for the three and nine months |
|
| November 5, 2025 |
Exhibit 99.1 Quantum-Si Reports Third Quarter 2025 Financial Results Announces Successful Sequencing on Prototype Proteus Unit, Development Program Remains On-Track BRANFORD, Conn. - (BUSINESS WIRE) - November 5, 2025 - Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics technology company redefining protein analysis through single-molecule detection, today a |
|
| November 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2025 QUANTUM-SI INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-39486 85-1388175 (State or other jurisdiction of incorporation) (Commissio |
|
| October 29, 2025 |
Up to $100,000,000 Class A Common Stock TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(3) Registration No. 333-290559 PROSPECTUS Up to $100,000,000 Class A Common Stock We have entered into a Sales Agreement (the “Sales Agreement”) with Leerink Partners LLC (“Leerink Partners”) relating to our Class A common stock, par value $0.0001 per share (“Class A common stock”), offered by this prospectus. In accordance with the terms of the |
|
| October 9, 2025 |
As filed with the Securities and Exchange Commission on October 9, 2025 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on October 9, 2025 Registration No. |
|
| September 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 26, 2025 QUANTUM-SI INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-39486 85-1388175 (State or other jurisdiction of incorporation) (Commiss |
|
| September 26, 2025 |
mutualreleaseagreement Page 1 of 6 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE OR CONFIDENTIAL. |
|
| September 26, 2025 |
QUANTUM-SI INCORPORATED [ ] Trustee Dated as of [ ] Subordinated Debt Securities TABLE OF CONTENTS1 Exhibit 4.4 QUANTUM-SI INCORPORATED Issuer AND [ ] Trustee INDENTURE Dated as of [ ] Subordinated Debt Securities TABLE OF CONTENTS1 Page ARTICLE I DEFINITIONS 1 SECTION 1.01 Definitions of Terms 1 ARTICLE II ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 SECTION 2.01 Designation and Terms of Securities 4 SECTION 2.02 Form of Securities and Trustee’s Certificate 5 |
|
| September 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 23, 2025 QUANTUM-SI INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-39486 85-1388175 (State or other jurisdiction of incorporation) (Commiss |
|
| September 26, 2025 |
QUANTUM-SI INCORPORATED [ ] Trustee Dated as of [ ] Senior Debt Securities TABLE OF CONTENTS1 Exhibit 4.3 QUANTUM-SI INCORPORATED Issuer AND [ ] Trustee INDENTURE Dated as of [ ] Senior Debt Securities TABLE OF CONTENTS1 Page ARTICLE I DEFINITIONS 1 SECTION 1.01 Definitions of Terms 1 ARTICLE II ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 SECTION 2.01 Designation and Terms of Securities 4 SECTION 2.02 Form of Securities and Trustee’s Certificate 5 SECTIO |
|
| September 26, 2025 |
As filed with the Securities and Exchange Commission on September 26, 2025 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on September 26, 2025 Registration No. |
|
| September 26, 2025 |
QUANTUM-SI INCORPORATED Shares of Class A Common Stock ($0.0001 par value per share) SALES AGREEMENT Exhibit 1.2 QUANTUM-SI INCORPORATED Shares of Class A Common Stock ($0.0001 par value per share) SALES AGREEMENT September 26, 2025 LEERINK PARTNERS LLC 1301 Avenue of the Americas, 5th Floor New York, New York 10019 Ladies and Gentlemen: Quantum-Si Incorporated, a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Leerink Partners LLC (the “Agent”), as follows: 1 |
|
| September 26, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Quantum-Si Incorporated (Exact Name of Registrant as Specified in Its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee(1)(2) Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid Equity Class A common stock, $0. |
|
| August 8, 2025 |
1 Corporate Presentation 2 Disclaimer and Other Information Forward-looking Statements This presentation includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. |
|
| August 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2025 QUANTUM-SI INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-39486 85-1388175 (State or other jurisdiction of incorporation) (Commission |
|
| August 5, 2025 |
Use of Non-GAAP Financial Measures Exhibit 99.2 Use of Non-GAAP Financial Measures In addition to financial results calculated in accordance with U.S. generally accepted accounting principles (“GAAP”), information containing non-GAAP financial measures for Quantum-Si Incorporated (the “Company”) was disclosed in the Company’s press release (the “Press Release”) dated August 5, 2025 announcing results for the three and six months en |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39486 QUANTUM-SI |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2025 QUANTUM-SI INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-39486 85-1388175 (State or other jurisdiction of incorporation) (Commission |
|
| August 5, 2025 |
Exhibit 99.1 Quantum-Si Reports Second Quarter 2025 Financial Results Announced On-Track ProteusTM Development Program Completes Capital Raise of $50 Million BRANFORD, Conn. - (BUSINESS WIRE) - August 5, 2025 - Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics technology company redefining protein analysis through single-molecule detection, today announced |
|
| July 7, 2025 |
PRE-FUNDED COMMON STOCK PURCHASE WARRANT QUANTUM-SI INCORPORATED Exhibit 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT QUANTUM-SI INCORPORATED Warrant Shares: Issue Date: July [•], 2025 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof |
|
| July 7, 2025 |
The date of this prospectus supplement is July 7, 2025. Filed Pursuant to Rule 424(b)(5) Registration No. 333-273934 PROSPECTUS SUPPLEMENT (To Prospectus Supplement dated December 11, 2024 and Prospectus dated August 22, 2023) This prospectus supplement supplements and amends certain information contained in the prospectus dated August 22, 2023 (the “Base Prospectus”), as supplemented by our prospectus supplement dated December 11, 2024 (the “Prospec |
|
| July 7, 2025 |
TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-273934 PROSPECTUS SUPPLEMENT (To Prospectus Dated August 22, 2023) 18,200,000 Shares of Class A Common Stock Pre-Funded Warrants to Purchase up to 11,740,119 Shares of Class A Common Stock Up to 11,740,119 Shares of Class A Common Stock Underlying the Pre- Funded Warrants Pursuant to this prospectus supplement and the ac |
|
| July 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 3, 2025 QUANTUM-SI INCORPORATED (Exact Name of Registrant as Specified in Charter) Delaware 001-39486 85-1388175 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| July 7, 2025 |
Quantum-Si Incorporated Announces Pricing of $50 Million Registered Direct Offering of Common Stock Exhibit 99.1 Quantum-Si Incorporated Announces Pricing of $50 Million Registered Direct Offering of Common Stock BRANFORD, Conn., July 3, 2025-(BUSINESS WIRE)-Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics technology company redefining protein analysis through single-molecule detection, today announced that it has entered into a securities purchase agree |
|
| July 7, 2025 |
[The remainder of this page has been intentionally left blank.] Exhibit 10.2 July 3, 2025 Quantum-SI Incorporated Attn: Jeffry Keyes, Chief Financial Officer 29 Business Park Drive Branford, Connecticut 06405 Dear Mr. Keyes: This letter (the “Agreement”) constitutes the agreement between A.G.P./Alliance Global Partners (the “Placement Agent”) and Quantum-SI Incorporated, a Delaware corporation (the “Company”), that the Placement Agent shall serve as the exclus |
|
| July 7, 2025 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of July 3, 2025, between Quantum-Si Incorporated, a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and conditions |
|
| May 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM SD Specialized Disclosure Report QUANTUM-SI INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-39486 85-1388175 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.) 29 Business Park Drive, Branford, Connecticut 06405 (Ad |
|
| May 22, 2025 |
Exhibit No. 1.01 - Conflict Minerals Report Exhibit 1.01 Section 1 – Conflict Minerals Disclosure Item 1.01 Conflict Minerals Disclosure and Report This Specialized Disclosure Form of Quantum-Si Incorporated (the “Company”) is being filed in accordance with Rule 13p-1 (the “Rule”) under the Securities Exchange Act of 1934, as amended, for the reporting period from January 1, 2024 to December 31, 2024 (the “Relevant Period”). The Rule impose |
|
| May 19, 2025 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2025 QUANTUM-SI INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-39486 85-1388175 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 15, 2025 |
Use of Non-GAAP Financial Measures Exhibit 99.2 Use of Non-GAAP Financial Measures In addition to financial results calculated in accordance with U.S. generally accepted accounting principles (“GAAP”), information containing non-GAAP financial measures for Quantum-Si Incorporated (the “Company”) was disclosed in the Company’s press release (the “Press Release”) dated May 15, 2025 announcing results for the three months ended March |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2025 QUANTUM-SI INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-39486 85-1388175 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 15, 2025 |
Exhibit 99.1 Quantum-Si Reports First Quarter 2025 Financial Results Launches and Delivers First Platinum® Pro Units Announces New Library Preparation Development Program BRANFORD, Conn. - (BUSINESS WIRE) - May 15, 2025 - Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced financial results for the first quarter ended March |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39486 QUANTUM-S |
|
| April 10, 2025 |
1 Corporate Presentation 2 Disclaimer and Other Information Forward-looking Statements This presentation includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. |
|
| April 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 10, 2025 QUANTUM-SI INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-39486 85-1388175 (State or other jurisdiction of incorporation) (Commission |
|
| March 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy Stat |
|
| March 20, 2025 |
ANNUAL REPORT 2024 www.quantum-si.com [THIS PAGE INTENTIONALLY LEFT BLANK] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition |
|
| March 20, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Def |
|
| March 3, 2025 |
Use of Non-GAAP Financial Measures Exhibit 99.2 Use of Non-GAAP Financial Measures In addition to financial results calculated in accordance with U.S. generally accepted accounting principles (“GAAP”), information containing non-GAAP financial measures for Quantum-Si Incorporated (the “Company”) was disclosed in the Company’s press release (the “Press Release”) dated March 3, 2025 announcing results for the fourth quarter and full |
|
| March 3, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Quantum-Si Incorporated (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Class A common stock, par value $0. |
|
| March 3, 2025 |
As filed with the Securities and Exchange Commission on March 3, 2025 As filed with the Securities and Exchange Commission on March 3, 2025 Registration No. |
|
| March 3, 2025 |
Exhibit 10.20 AMENDED AND RESTATED QUANTUM-SI INCORPORATED EXECUTIVE SEVERANCE PLAN PLAN DOCUMENT AND SUMMARY PLAN DESCRIPTION Effective as of November 1, 2024 1.Establishment of Plan. Quantum-Si Incorporated (the “Company”), hereby establishes an unfunded severance benefits plan (this “Plan”) that is intended to be a welfare benefit plan within the meaning of Section 3(1) of ERISA. This Plan, ori |
|
| March 3, 2025 |
Exhibit 99.1 Quantum-Si Reports Fourth Quarter and Full Year 2024 Financial Results Achieves First Quarterly Revenue Over $1 Million Completes Capital Raises of $86 Million BRANFORD, Conn. - (BUSINESS WIRE) - March 3, 2025 - Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced financial results for the fourth quarter and ful |
|
| March 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2025 QUANTUM-SI INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-39486 85-1388175 (State or other jurisdiction of incorporation) (Commission F |
|
| March 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File Number: 001-39486 QUANTUM- |
|
| March 3, 2025 |
Exhibit 19.1 QUANTUM- SI INCORPORATED INSIDER TRADING POLICY (Effective February 2025) TABLE OF CONTENTS Page I. The Need for an Insider Trading Policy 2 II. What is Material Non-Public Information? 2 III. The Consequences of Insider Trading 4 IV. Our Policy 5 General Prohibition on Trading 5 Transactions by Family Members, Others in Your Household and Entities You Control 5 Other Companies’ Non-p |
|
| February 13, 2025 |
EX-99.1 2 ef20043545ex99-1.htm EXHIBIT A Exhibit A Pursuant to the instructions in Items 6 and 7 of Schedule 13G, the security being reported on by Nikko Asset Management Americas, Inc., as subsidiary to the parent holding companies listed below, are owned, or may be deemed to be beneficially owned, by its parent holding companies. 1) Sumitomo Mitsui Trust Group Inc. o A parent holding company or |
|
| January 6, 2025 |
EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of January 3, 2025, between Quantum-Si Incorporated, a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and conditio |
|
| January 6, 2025 |
15,625,000 Shares of Class A Common Stock TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-273934 PROSPECTUS SUPPLEMENT (To Prospectus Dated August 22, 2023) 15,625,000 Shares of Class A Common Stock Pursuant to this prospectus supplement and the accompanying prospectus, we are offering in a registered direct offering to certain purchasers 15,625,000 shares of our Class A common stock, par value $0.0001 per share |
|
| January 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2025 QUANTUM-SI INCORPORATED (Exact Name of Registrant as Specified in Charter) Delaware 001-39486 85-1388175 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| January 6, 2025 |
Quantum-Si Incorporated Announces Pricing of $50 Million Registered Direct Offering of Common Stock Exhibit 99.1 Quantum-Si Incorporated Announces Pricing of $50 Million Registered Direct Offering of Common Stock BRANFORD, Conn., January 3, 2025-(BUSINESS WIRE)-Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced that it has entered into securities purchase agreements with certain institutional investors for the purchase a |
|
| January 6, 2025 |
[The remainder of this page has been intentionally left blank.] Exhibit 10.2 January 3, 2025 Quantum-SI Incorporated Attn: Jeffry Keyes, Chief Financial Officer 29 Business Park Drive Branford, Connecticut 06405 Dear Mr. Keyes: This letter (the “Agreement”) constitutes the agreement between A.G.P./Alliance Global Partners (the “Placement Agent”) and Quantum-SI Incorporated, a Delaware corporation (the “Company”), that the Placement Agent shall serve as the exc |
|
| December 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2024 QUANTUM-SI INCORPORATED (Exact Name of Registrant as Specified in Charter) Delaware 001-39486 85-1388175 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| December 11, 2024 |
Up to $75,000,000 Class A Common Stock TABLE OF CONTENTS Filed pursuant to Rule 424(b)(5) Registration No. 333-273934 PROSPECTUS SUPPLEMENT (To Prospectus Dated August 22, 2023) Up to $75,000,000 Class A Common Stock We have entered into an Equity Distribution Agreement (the “Equity Distribution Agreement”) with Canaccord Genuity LLC (“Canaccord”) relating to our Class A common stock, par value $0.0001 per share (“Class A common st |
|
| December 11, 2024 |
Exhibit 10.1 QUANTUM-SI INCORPORATED Class A Common Stock (par value $0.0001 per share) Having an Aggregate Offering Price of Up to $75,000,000 Equity Distribution Agreement December 11, 2024 Canaccord Genuity LLC 1 Post Office Square, Suite 3000 Boston, Massachusetts 02109 Ladies and Gentlemen: Quantum-Si Incorporated, a Delaware corporation (the “Company”) confirms its agreement (this “Agreement |
|
| December 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 4, 2024 QUANTUM-SI INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-39486 85-1388175 (State or other jurisdiction of incorporation) (Commissio |
|
| November 22, 2024 |
Costs Associated with Exit or Disposal Activities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 21, 2024 QUANTUM-SI INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-39486 85-1388175 (State or other jurisdiction of incorporation) (Commissi |
|
| November 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2024 QUANTUM-SI INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-39486 85-1388175 (State or other jurisdiction of incorporation) (Commissi |
|
| November 21, 2024 |
Exhibit 99.1 Investor & Analyst Day November 20, 2024 Forward Looking Statements This presentation includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. The actual results of the Company may differ from its expectations, estimates, and projections and, consequently, you should not rely on thes |
|
| November 12, 2024 |
Exhibit 10.2 August 22, 2024 TODD BENNETT Dear Todd: On behalf of Quantum-Si, I am pleased to offer you a position as Chief Commercial Officer beginning September 17, 2024. You will report to Jeff Hawkins. Your annualized compensation in this position will consist of an annual base salary of $425,000 paid in twice monthly pay periods, less required deductions. For calendar year 2024, you will be e |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 QUANTUM-SI INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-39486 85-1388175 (State or other jurisdiction of incorporation) (Commissi |
|
| November 12, 2024 |
Exhibit 99.1 Quantum-Si Reports Third Quarter 2024 Financial Results Sales Pipeline is Accelerating and New Kits Remain on Track for Q4 Launch BRANFORD, Conn. - (BUSINESS WIRE) - November 12, 2024 - Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced financial results for the third quarter ended September 30, 2024. Press Re |
|
| November 12, 2024 |
Exhibit 10.1 August 12, 2024 JOHN VIECELI Dear John: Congratulations. This letter confirms the terms of your employment in connection with your promotion to Chief Product Officer. We are pleased to inform you that your new annual base salary will be $395,000 to be paid twice per month, less required deductions. This is effective August 12, 2024. In addition, your new bonus target will be 50% prora |
|
| November 12, 2024 |
QUANTUM-SI INCORPORATED 2023 INDUCEMENT EQUITY INCENTIVE PLAN (As Amended on August 23, 2024) Exhibit 10.3 QUANTUM-SI INCORPORATED 2023 INDUCEMENT EQUITY INCENTIVE PLAN (As Amended on August 23, 2024) 1.DEFINITIONS. Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this Quantum-Si Incorporated 2023 Inducement Equity Incentive Plan, have the following meanings: Administrator means the Board of Directors, unless it has delegated power to act |
|
| November 12, 2024 |
Exhibit 10.3.1 QUANTUM-SI INCORPORATED Restricted Stock Unit Award Grant Notice Restricted Stock Unit Grant under the Company’s 2023 Inducement Equity Incentive Plan Name: Grant Number: Grant Date: Grant Type: Grant Shares: Vesting of Award: This Restricted Stock Unit Award shall vest as follows provided the Participant is an Employee of the Company or of an Affiliate on the applicable vesting dat |
|
| November 12, 2024 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2024 QUANTUM-SI INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-39486 85-1388175 (State or other jurisdiction of incor |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39486 QUANT |
|
| November 12, 2024 |
Use of Non-GAAP Financial Measures Exhibit 99.2 Use of Non-GAAP Financial Measures In addition to financial results calculated in accordance with U.S. generally accepted accounting principles (“GAAP”), information containing non-GAAP financial measures for Quantum-Si Incorporated (the “Company”) was disclosed in the Company’s press release (the “Press Release”) dated November 12, 2024 announcing results for the three and nine month |
|
| November 8, 2024 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2024 QUANTUM-SI INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-39486 85-1388175 (State or other jurisdiction of incorporation) (Commissio |
|
| September 17, 2024 |
[Remainder of Page Intentionally Left Blank – Signature Page Follows] EX-4 2 ef20035967ex4.htm EXHIBIT 4 Exhibit 4 520 Madison Avenue, New York, NY 10022 212.284.2300 Rule 10B5-1 Sales Plan Section 16 Affiliate I. Customer Information Capitalized terms that are used but not defined in this section shall have the meanings set forth in Part IV, Terms and Conditions. Seller: Jonathan Rothberg acting on his own and on behalf of NVR TR, LLC, JNR TR, LLC, JAR TR, LLC, EJR |
|
| September 17, 2024 |
QSI / Quantum-Si incorporated / ROTHBERG JONATHAN M - SC 13D/A Activist Investment SC 13D/A 1 ef20035967sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Quantum-Si Incorporated (Name of Issuer) Class A common stock, par value $0.0001 per share Class B common stock, par value $0.0001 per share (Title of Class of Securities) Class A common stock: 74765K105 Class B c |
|
| August 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 21, 2024 QUANTUM-SI INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-39486 85-1388175 (State or other jurisdiction of incorporation) (Commission |
|
| August 27, 2024 |
Exhibit 99.1 Quantum-Si Announces New Executive Team Members to Accelerate the Evolution of the Company into a Leading Proteomic Tool Provider BRANFORD, Conn.-(BUSINESS WIRE)—August 27, 2024- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced that Todd Bennett will join QSI as the Company’s new Chief Commercial Officer eff |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2024 QUANTUM-SI INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-39486 85-1388175 (State or other jurisdiction of incorporation) (Commission |
|
| August 13, 2024 |
Exhibit 99.1 Corporate Presentation Forward Looking Statements This presentation includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. The actual results of Quantum-Si Incorporated (the “Company”) may differ from its expectations, estimates, and projections and, consequently, you should not re |
|
| August 7, 2024 |
Use of Non-GAAP Financial Measures Exhibit 99.2 Use of Non-GAAP Financial Measures In addition to financial results calculated in accordance with U.S. generally accepted accounting principles (“GAAP”), information containing non-GAAP financial measures for Quantum-Si Incorporated (the “Company”) was disclosed in the Company’s press release (the “Press Release”) dated August 7, 2024 announcing results for the three and six months en |
|
| August 7, 2024 |
SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF HIGHCAPE CAPITAL ACQUISITION CORP. Exhibit 3.1 SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF HIGHCAPE CAPITAL ACQUISITION CORP. HighCape Capital Acquisition Corp., a corporation organized and existing under the General Corporation Law of the State of Delaware (the “DGCL”), hereby certifies as follows: 1. The name of this corporation is HighCape Capital Acquisition Corp. The date of the filing of its original certifica |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39486 QUANTUM-SI |
|
| August 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2024 QUANTUM-SI INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-39486 85-1388175 (State or other jurisdiction of incorporation) (Commission |
|
| August 7, 2024 |
Exhibit 99.1 Quantum-Si Reports Second Quarter 2024 Financial Results Announces Release of Version 3 Sequencing Kit Announces Two Additional Kit Launches Expected by End of 2024 BRANFORD, Conn. - (BUSINESS WIRE) - August 7, 2024 - Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced financial results for the second quarter e |
|
| June 28, 2024 |
QSI / Quantum-Si incorporated / Radcliffe Capital Management, L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 2) Quantum-Si Inc [f/k/a HighCape Capital Acquisition Corp.] (Name of Issuer) Class A ordinary shares, $0.0001 par value (Title of Class of Sec |
|
| June 25, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2024 QUANTUM-SI INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-39486 85-1388175 (State or other jurisdiction of incorporation) (Commission F |
|
| June 25, 2024 |
Exhibit 99.1 Corporate Presentation Forward Looking Statements This presentation includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. The actual results of Quantum-Si Incorporated (the “Company”) may differ from its expectations, estimates, and projections and, consequently, you should not re |
|
| June 21, 2024 |
Exhibit 24.1 POWER OF ATTORNEY Know all by these present, that the undersigned hereby constitutes and appoints each of Jeffry Keyes, Chief Financial Officer, Christian LaPointe, Ph.D., General Counsel, and Linda Spero, Director of SEC Reporting, of Quantum-Si Incorporated (the “Company”), and Michael Fantozzi, Anne Bruno, Samantha Silver, Maura Foley and Robyn Frattali of Mintz, Levin, Cohn, Ferri |
|
| June 7, 2024 |
Exhibit 16.1 June 7, 2024 Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-7561 Dear Sirs/Madams: We have read Item 4.01 of Quantum-Si Incorporated’s Form 8-K dated June 7, 2024, and have the following comments: 1. We agree with the statements made in paragraphs 2, 3, 4, 5 and 6 therein. 2. We have no basis on which to agree or disagree with the statements made in parag |
|
| June 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2024 QUANTUM-SI INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-39486 85-1388175 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 30, 2024 |
Exhibit 99.1 Quantum-Si Appoints Former Bio-Techne President and CEO, Chuck Kummeth, to serve as independent Chairman of the Board of Directors BRANFORD, Conn.-(BUSINESS WIRE)—May 30, 2024- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing CompanyTM, today announced the appointment of Charles ("Chuck") Kummeth to the role of independent Chairman o |
|
| May 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 27, 2024 QUANTUM-SI INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-39486 85-1388175 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2024 QUANTUM-SI INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-39486 85-1388175 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2024 QUANTUM-SI INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-39486 85-1388175 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 17, 2024 |
CERTIFICATE OF AMENDMENT CERTIFICATE OF INCORPORATION QUANTUM-SI INCORPORATED Exhibit 3.1 CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION OF QUANTUM-SI INCORPORATED It is hereby certified that: FIRST: The name of the corporation is Quantum-Si Incorporated (the “Corporation”). SECOND: The Certificate of Incorporation is hereby further amended by striking out Article VIII, Part B in its entirety and by substituting in lieu of the following: (B) Number of Directors. S |
|
| May 9, 2024 |
Use of Non-GAAP Financial Measures Exhibit 99.2 Use of Non-GAAP Financial Measures In addition to financial results calculated in accordance with U.S. generally accepted accounting principles (“GAAP”), information containing non-GAAP financial measures for Quantum-Si Incorporated (the “Company”) was disclosed in the Company's press release (the “Press Release”) dated May 9, 2024 announcing results for the three months ended March 3 |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39486 QUANTUM-S |
|
| May 9, 2024 |
Exhibit 99.1 Quantum-Si Reports First Quarter 2024 Financial Results Executed Full Commercial Launch of Platinum® Instrument Reaffirms Full Year 2024 Financial Guidance BRANFORD, Conn. - (BUSINESS WIRE) – May 9, 2024 - Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing CompanyTM, today announced financial results for the first quarter ended March 3 |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 QUANTUM-SI INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-39486 85-1388175 (State or other jurisdiction of incorporation) (Commission Fil |
|
| April 30, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rul |
|
| April 9, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 9, 2024 QUANTUM-SI INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-39486 85-1388175 (State or other jurisdiction of incorporation) (Commission F |
|
| April 9, 2024 |
Exhibit 99.1 Corporate Presentation April 2024 Forward Looking Statements This presentation includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. The actual results of Quantum-Si Incorporated (the “Company”) may differ from its expectations, estimates, and projections and, consequently, you sh |
|
| April 1, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rul |
|
| April 1, 2024 |
ANNUAL REPORT 2023 www.quantum-si.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K 侌 ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or 侊 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe |
|
| April 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi |
|
| March 22, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| March 21, 2024 |
Exhibit 99.1 Quantum-Si Appoints Former Illumina and Cisco Systems Executive, Paula Dowdy, to its Board of Directors BRANFORD, Conn.-(BUSINESS WIRE)—March 21, 2024- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing CompanyTM, today announced the appointment of Paula Dowdy, a senior executive with more than 35 years of experience across life scienc |
|
| March 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2024 QUANTUM-SI INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-39486 85-1388175 (State or other jurisdiction of incorporation) (Commission |
|
| March 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2024 QUANTUM-SI INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-39486 85-1388175 (State or other jurisdiction of incorporation) (Commission F |
|
| February 29, 2024 |
QUANTUM-SI INCORPORATED NONEMPLOYEE DIRECTOR COMPENSATION POLICY (As Amended on February 27, 2024) Exhibit 10.16 QUANTUM-SI INCORPORATED NONEMPLOYEE DIRECTOR COMPENSATION POLICY (As Amended on February 27, 2024) The Board of Directors of Quantum-Si Incorporated (the “Company”) has approved the following Nonemployee Director Compensation Policy (this “Policy”) to provide an inducement to obtain and retain the services of qualified persons to serve as members of the Company’s Board of Directors. |
|
| February 29, 2024 |
As filed with the Securities and Exchange Commission on February 29, 2024 As filed with the Securities and Exchange Commission on February 29, 2024 Registration No. |
|
| February 29, 2024 |
Use of Non-GAAP Financial Measures Exhibit 99.2 Use of Non-GAAP Financial Measures In addition to financial results calculated in accordance with U.S. generally accepted accounting principles (“GAAP”), information containing non-GAAP financial measures for Quantum-Si Incorporated (the “Company”) was disclosed in the Company's press release (the “Press Release”) dated February 29, 2024 announcing results for the three months and ful |
|
| February 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39486 QUANTUM-SI INCORPORATED ( |
|
| February 29, 2024 |
Exhibit 10.13.3 QUANTUM-SI INCORPORATED Restricted Stock Unit Award Grant Notice Restricted Stock Unit Grant under the Company’s 2021 Equity Incentive Plan Name: Grant Number: Grant Date: Grant Type: Grant Shares: Vesting of Award: This Restricted Stock Unit Award shall vest as follows provided the Participant is an Employee, director or Consultant of the Company or of an Affiliate on the applicab |
|
| February 29, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Quantum-Si Incorporated (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Class A common stock, par value $0. |
|
| February 29, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 29, 2024 QUANTUM-SI INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-39486 85-1388175 (State or other jurisdiction of incorporation) (Commissi |
|
| February 29, 2024 |
QUANTUM-SI INCORPORATED CLAWBACK POLICY Exhibit 97 QUANTUM-SI INCORPORATED CLAWBACK POLICY I. Introduction The Board of Directors (the “Board”) of Quantum-Si Incorporated (the “Company”) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation philosophy. The Board has ther |
|
| February 29, 2024 |
Exhibit 99.1 Quantum-Si Reports Fourth Quarter and Full Year 2023 Financial Results Finalizing Commercial Readiness for Expected Full Commercial Launch by the End of Q1 2024 Releases Full Year 2024 Financial Guidance BRANFORD, Conn. - (BUSINESS WIRE) – Feb. 29, 2024 - Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing CompanyTM, today announced fin |
|
| February 29, 2024 |
DESCRIPTION OF THE REGISTRANT’S SECURITIES Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES The following summary of the material terms of the capital stock of Quantum-Si Incorporated (formerly HighCape Capital Acquisition Corp.) is not intended to be a complete summary of the rights and preferences of such securities, and is qualified by reference to our Second Amended and Restated Certificate of Incorporation, as amended (the “Char |
|
| February 13, 2024 |
QSI / Quantum-Si incorporated / Nikko Asset Management Americas, Inc. - SC 13G Passive Investment SC 13G 1 ef20021430sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a)* Quantum-Si Inc. (Name of Issuer) Class A common stock, par value $0.0001 per share (Title of Class of Securities) 74765K105 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Che |
|
| February 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 5, 2024 QUANTUM-SI INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-39486 85-1388175 (State or other jurisdiction of incorporation) (Commissio |
|
| February 5, 2024 |
QSI / Quantum-Si incorporated / Sumitomo Mitsui Trust Holdings, Inc. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a)* QUANTUM-SI INCORPORATED (Name of Issuer) Class A common stock, par value $0.0001 per share (Title of Class of Securities) 74765K105 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to de |
|
| February 5, 2024 |
Exhibit 99.1 Quantum-Si Expands Proteome Coverage and Increases Sequencing Output with New Enhancements to Its Next-Generation Protein Sequencing™ Platform Addition of another amino acid recognizer combined with improvements in surface chemistry, reagents and software will offer Platinum users greater sequencing output and coverage per sample BRANFORD, Conn. – (BUSINESS WIRE) – February 5, 2024 - |
|
| January 29, 2024 |
QSI / Quantum-Si incorporated / BlackRock Inc. Passive Investment us74765k1051012924.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 1) Quantum-Si Inc - (Name of Issuer) Common Stock - (Title of Class of Securities) 74765K105 - (CUSIP Number) December 31, 2023 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whi |
|
| January 29, 2024 |
QSI / Quantum-Si incorporated / ARK Investment Management LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39486 QUANT |
|
| November 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2023 QUANTUM-SI INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-39486 85-1388175 (State or other jurisdiction of incorporation) (Commissio |
|
| November 9, 2023 |
Use of Non-GAAP Financial Measures Exhibit 99.2 Use of Non-GAAP Financial Measures In addition to financial results calculated in accordance with U.S. generally accepted accounting principles (“GAAP”), information containing non-GAAP financial measures for Quantum-Si Incorporated (the “Company”) was disclosed in the Company's press release (the “Press Release”) dated November 9, 2023 announcing results for the three and nine months |
|
| November 9, 2023 |
Quantum-Si Reports Third Quarter 2023 Financial Results Exhibit 99.1 Quantum-Si Reports Third Quarter 2023 Financial Results BRANFORD, Conn. - (BUSINESS WIRE) – Nov. 9, 2023 - Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing CompanyTM, today announced financial results for the third quarter ended September 30, 2023. Third Quarter Highlights ● Recorded revenue of $223,000 in the third quarter of 2023 a |
|
| September 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2023 QUANTUM-SI INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-39486 85-1388175 (State or other jurisdiction of incorporation) (Commiss |
|
| September 21, 2023 |
Quantum-Si Appoints Biotech Executive and Entrepreneur, Amir Jafri, to its Board of Directors Exhibit 99.1 Quantum-Si Appoints Biotech Executive and Entrepreneur, Amir Jafri, to its Board of Directors BRANFORD, Conn. - (BUSINESS WIRE) - September 21, 2023 – Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced the appointment of Amir Jafri, President and CEO of Immunicom, Inc., to its Board of Directors. “Amir’s leade |
|
| September 13, 2023 |
QSI / Quantum-Si Incorporated - Class A / ROTHBERG JONATHAN M - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Quantum-Si Incorporated (Name of Issuer) Class A common stock, par value $0.0001 per share Class B common stock, par value $0.0001 per share (Title of Class of Securities) Class A common stock: 74765K105 Class B common stock: Not Applicable (CUSIP Number |
|
| September 13, 2023 |
EX-3 2 ef20010600ex3.htm EXHIBIT 3 Exhibit 3 Rule 10b5-1 Sales Plan This Rule 10b5-1 Sales Plan is entered into on September 11, 2023 (this “Sales Plan”) between Dr. Jonathan Rothberg (“Seller”), acting on his own behalf and on behalf of each of: NVR TR, LLC, JNR TR, LLC, JAR TR, LLC, EJR TR, LLC and GBR TR, LLC (each a “Selling Entity”), and Jefferies LLC (“Broker”), acting as agent for Seller. R |
|
| September 5, 2023 |
Exhibit 10.1 August 30, 2023 Patrick Schneider Re: Separation Agreement Dear Patrick: The purpose of this letter agreement (this “Agreement”) is to confirm the end of your employment with Quantum-Si Incorporated (the “Company”) as of August 31, 2023 (the “Separation Date”), and to set forth the terms of your separation from Quantum-Si Incorporated (“Company”). Payment of the Separation Benefits de |
|
| September 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 1, 2023 QUANTUM-SI INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-39486 85-1388175 (State or other jurisdiction of incorporation) (Commissi |
|
| August 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 26, 2023 QUANTUM-SI INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-39486 85-1388175 (State or other jurisdiction of incorporation) (Commission |
|
| August 18, 2023 |
United States securities and exchange commission logo August 18, 2023 Jeffrey Hawkins Chief Executive Officer Quantum-Si Incorporated 29 Business Park Drive Branford, Connecticut 06405 Re: Quantum-Si Incorporated Registration Statement on Form S-3 Filed August 11, 2023 File No. |
|
| August 18, 2023 |
QUANTUM-SI INCORPORATED 29 Business Park Drive Branford, CT 06405 QUANTUM-SI INCORPORATED 29 Business Park Drive Branford, CT 06405 August 18, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| August 11, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Quantum-Si Incorporated (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to Be Paid Equity Class A common stock, $0. |
|
| August 11, 2023 |
QUANTUM-SI INCORPORATED [ ] Trustee Dated as of [ ] Subordinated Debt Securities TABLE OF CONTENTS1 Exhibit 4.2 QUANTUM-SI INCORPORATED Issuer AND [ ] Trustee INDENTURE Dated as of [ ] Subordinated Debt Securities TABLE OF CONTENTS1 Page ARTICLE I DEFINITIONS 1 SECTION 1.01 Definitions of Terms 1 ARTICLE II ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 SECTION 2.01 Designation and Terms of Securities 4 SECTION 2.02 Form of Securities and Trustee’s Certificate 6 |
|
| August 11, 2023 |
Exhibit 1.2 QUANTUM-SI INCORPORATED Class A Common Stock (par value $0.0001 per share) Having an Aggregate Offering Price of Up to $75,000,000 Equity Distribution Agreement August 11, 2023 Evercore Group L.L.C. 55 East 52nd Street, 36th Floor New York, New York 10055 Ladies and Gentlemen: Quantum-Si Incorporated, a Delaware corporation (the “Company”) confirms its agreement (this “Agreement”) with |
|
| August 11, 2023 |
As filed with the Securities and Exchange Commission on August 11, 2023 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on August 11, 2023 Registration No. |
|
| August 11, 2023 |
QUANTUM-SI INCORPORATED [ ] Trustee Dated as of [ ] Senior Debt Securities TABLE OF CONTENTS1 Exhibit 4.1 QUANTUM-SI INCORPORATED Issuer AND [ ] Trustee INDENTURE Dated as of [ ] Senior Debt Securities TABLE OF CONTENTS1 Page ARTICLE I DEFINITIONS 1 SECTION 1.01 Definitions of Terms 1 ARTICLE II ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 SECTION 2.01 Designation and Terms of Securities 4 SECTION 2.02 Form of Securities and Trustee’s Certificate 6 SECTIO |
|
| August 7, 2023 |
Quantum-Si Reports Second Quarter 2023 Financial Results Exhibit 99.1 Quantum-Si Reports Second Quarter 2023 Financial Results BRANFORD, Conn. - (BUSINESS WIRE) - Aug. 7, 2023 - Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing CompanyTM, today announced financial results for the second quarter ended June 30, 2023. Second Quarter Highlights ● Recognized revenue of $205,000 in the second quarter of 2023. |
|
| August 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39486 QUANTUM-SI |
|
| August 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2023 QUANTUM-SI INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-39486 85-1388175 (State or other jurisdiction of incorporation) (Commission |
|
| August 7, 2023 |
SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF HIGHCAPE CAPITAL ACQUISITION CORP. Exhibit 3.1 SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF HIGHCAPE CAPITAL ACQUISITION CORP. HighCape Capital Acquisition Corp., a corporation organized and existing under the General Corporation Law of the State of Delaware (the “DGCL”), hereby certifies as follows: 1. The name of this corporation is HighCape Capital Acquisition Corp. The date of the filing of its original certifica |
|
| July 20, 2023 |
Exhibit 10.1 June 26, 2023 Michael McKenna Re: Separation Agreement Dear Mike: The purpose of this letter agreement (this “Agreement”) is to confirm the end of your employment with Quantum-Si Incorporated (the “Company”) as of July 31, 2023 (the “Separation Date”), and to set forth the terms of your separation from Quantum-Si Incorporated (“Company”). Payment of the Separation Benefits described b |
|
| July 20, 2023 |
QUANTUM-SI INCORPORATED 2023 INDUCEMENT EQUITY INCENTIVE PLAN Exhibit 99.1 QUANTUM-SI INCORPORATED 2023 INDUCEMENT EQUITY INCENTIVE PLAN 1. DEFINITIONS. Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this Quantum-Si Incorporated 2023 Inducement Equity Incentive Plan, have the following meanings: Administrator means the Board of Directors, unless it has delegated power to act on its behalf to the Committee |
|
| July 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 18, 2023 QUANTUM-SI INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-39486 85-1388175 (State or other jurisdiction of incorporation) (Commission F |
|
| July 20, 2023 |
As filed with the Securities and Exchange Commission on July 20, 2023 As filed with the Securities and Exchange Commission on July 20, 2023 Registration No. |
|
| July 20, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Quantum-Si Incorporated (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Class A common stock, par value $0. |
|
| July 20, 2023 |
Exhibit 99.2 QUANTUM-SI INCORPORATED Stock Option Grant Notice Stock Option Grant under the Company’s 2023 Inducement Equity Incentive Plan Name: Grant Number: Grant Date: Vest Commencement Date: Grant Type: Non-Qualified Stock Option Grant Shares: Exercise Price: Expiration Date: Vesting Schedule: This Option shall become exercisable (and the Shares issued upon exercise shall be vested) as follow |
|
| July 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| June 21, 2023 |
Exhibit 99.1 Quantum-Si Announces the Appointment of Industry Veteran Johan Denecke as Senior Vice President of Operations BRANFORD, Conn., June 21, 2023 — Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced the appointment of Johan Denecke as Senior Vice President of Operations, effective June 20, 2023. Mr. Denecke will be |
|
| June 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2023 QUANTUM-SI INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-39486 85-1388175 (State or other jurisdiction of incorporation) (Commission F |
|
| June 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2023 QUANTUM-SI INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-39486 85-1388175 (State or other jurisdiction of incorporation) (Commission Fi |
|
| June 7, 2023 |
Exhibit 10.1 June 1, 2023 Claudia Drayton Re: Separation Agreement Dear Claudia: The purpose of this letter agreement (this “Agreement”) is to confirm the end of your employment with Quantum-Si Incorporated (the “Company”) as of June 30, 2022, and to set forth the terms of your separation from Quantum-Si Incorporated (“Company”). Payment of the Separation Benefits described below is contingent on |
|
| May 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2023 QUANTUM-SI INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-39486 85-1388175 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 22, 2023 |
Exhibit 99.1 Quantum-Si Appoints Life Sciences and Diagnostics Industry Leader Jack Kenny to its Board of Directors GUILFORD, Conn. – May 22, 2023 – Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced the appointment of Jack Kenny, CEO of Meridian Bioscience, Inc., to its Board of Directors. “Jack brings a wealth of experie |
|
| May 16, 2023 |
CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION OF QUANTUM-SI INCORPORATED It is hereby certified that: FIRST: The name of the corporation is Quantum-Si Incorporated (the “Corporation”). |
|
| May 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 QUANTUM-SI INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-39486 85-1388175 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 11, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 QUANTUM-SI INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-39486 85-1388175 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 11, 2023 |
Exhibit 99.1 Quantum-Si Reports First Quarter 2023 Financial Results Q1 2023 revenue $254,000 on orders of $449,000; gross margin 48.8% This was the Company’s first quarter of revenue generated on the sale of PlatinumTM instruments and kits Expect revenue to accelerate in the second half of 2023 based on robust business funnel GUILFORD, Conn. - (BUSINESS WIRE) - May 11, 2023 - Quantum-Si Incorpora |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39486 QUANTUM-S |
|
| May 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2023 QUANTUM-SI INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-39486 85-1388175 (State or other jurisdiction of incorporation) (Commission |
|
| May 2, 2023 |
Exhibit 10.1 April 27, 2023 Jeffry Keyes Dear Jeffry: On behalf of Quantum-Si, I am pleased to offer you a position as Chief Financial Officer beginning as soon as practical. You will report to Jeffrey Hawkins. Your annualized compensation in this position will consist of an annual base salary of $465,000 paid in twice monthly pay periods, less required deductions. For calendar year 2023, you will |
|
| May 2, 2023 |
Exhibit 99.1 Quantum-Si Announces the Appointment of Jeff Keyes as Chief Financial Officer Appointment positions company for strategic growth in next-generation protein sequencing GUILFORD, Conn., May 2, 2023 — Quantum-Si- Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced the appointment of Jeff Keyes as its new Chief Financial Offi |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or □ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39486 QUANTUM-SI INC |
|
| March 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi |
|
| March 29, 2023 |
DEF 14A 1 ny20007250x4def14a.htm DEF 14A TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| March 17, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| March 17, 2023 |
Services Work Order No. 2 Protein Engineering Collaboration March 13, 2023 Exhibit 10.14 Services Work Order No. 2 Protein Engineering Collaboration March 13, 2023 This Services Work Order (“Work Order”) is made pursuant to, and is governed by, the Technology and Services Exchange Agreement (“TSEA”) between Quantum-Si Incorporated (“Q-Si”) and Protein Evolution, Inc. (“PEI”), joined by PEI on August 11, 2021 and made effective as of the Effective Time (as defined in the |
|
| March 17, 2023 |
EX-10.6 3 brhc10049653ex10-6.htm EXHIBIT 10.6 Exhibit 10.6 ADVISORY AGREEMENT This ADVISORY AGREEMENT (the “Agreement”) is entered into as of November 1, 2022 (the “Effective Date”), by and between Quantum-Si Incorporated, a Delaware corporation (the “Company”), and Jonathan Rothberg, PhD. (“Dr. Rothberg”). WHEREAS, Dr. Rothberg serves on the Board of Directors of the Company (the “Board”) and as |
|
| March 17, 2023 |
QUANTUM-SI INCORPORATED NONEMPLOYEE DIRECTOR COMPENSATION POLICY (As Amended on November 1, 2022) EX-10.18 6 brhc10049653ex10-18.htm EXHIBIT 10.18 Exhibit 10.18 QUANTUM-SI INCORPORATED NONEMPLOYEE DIRECTOR COMPENSATION POLICY (As Amended on November 1, 2022) The Board of Directors of Quantum-Si Incorporated (the “Company”) has approved the following Nonemployee Director Compensation Policy (this “Policy”) to provide an inducement to obtain and retain the services of qualified persons to serve |
|
| March 17, 2023 |
As filed with the Securities and Exchange Commission on March 16, 2023 As filed with the Securities and Exchange Commission on March 16, 2023 Registration No. |
|
| March 17, 2023 |
Exhibit 10.9 December 8, 2022 GRACE JOHNSTON Dear Grace: On behalf of Quantum-Si, I am pleased to offer you a position as Chief Commercial Officer beginning as soon as practical. You will report to Jeff Hawkins. Your annualized compensation in this position will consist of an annual base salary of $420,000 paid in twice monthly pay periods, less required deductions. For calendar year 2023, you wil |
|
| March 17, 2023 |
DESCRIPTION OF THE REGISTRANT’S SECURITIES Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES The following summary of the material terms of the capital stock of Quantum-Si Incorporated (formerly HighCape Capital Acquisition Corp.) is not intended to be a complete summary of the rights and preferences of such securities, and is qualified by reference to our Second Amended and Restated Certificate of Incorporation (the “Charter”), our A |
|
| March 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39486 QUANTUM-SI INC |
|
| March 17, 2023 |
EX-21.1 7 brhc10049653ex21-1.htm EXHIBIT 21.1 Exhibit 21.1 Subsidiaries of Registrant Name Percentage Ownership State or Country of Organization Q-SI Operations Inc. 100% Delaware SAS Quantum-Si France 100% France |
|
| March 17, 2023 |
EX-FILING FEES 4 brhc10049719ex107.htm EXHIBIT 107 Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Quantum-Si Incorporated (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price Fee Rate Amou |
|
| March 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2023 QUANTUM-SI INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-39486 85-1388175 (State or other jurisdiction of incorporation) (Commission |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 QUANTUM-SI INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-39486 85-1388175 (State or other jurisdiction of incorporation) (Commission |
|
| March 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2023 QUANTUM-SI INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-39486 85-1388175 (State or other jurisdiction of incorporation) (Commission F |
|
| March 6, 2023 |
Exhibit 99.1 Quantum-Si Reports Fourth Quarter and Fiscal Year 2022 Financial Results The Company began shipments of PlatinumTM instruments and expects to book revenue in Q1 2023 The Company projects an extended cash runway into 2026 GUILFORD, Conn. - (BUSINESS WIRE) - Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing CompanyTM, today announced fi |
|
| March 2, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2023 QUANTUM-SI INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-39486 85-1388175 (State or other jurisdiction of incorporation) (Commissi |
|
| March 2, 2023 |
IN THE COURT OF CHANCERY FOR THE STATE OF DELAWARE Exhibit 99.1 IN THE COURT OF CHANCERY FOR THE STATE OF DELAWARE IN RE QUANTUM-SI INCORPORATED ) ) ) C.A. No. 2023- VERIFIED PETITION FOR RELIEF UNDER 8 DEL. C. § 205 Petitioner Quantum-Si Incorporated (“Quantum-Si” or the “Company”) brings this petition (the “Petition”) for relief under Section 205 of the Delaware General Corporation Law (the “DGCL”): NATURE OF THE ACTION 1. The Company seeks to v |
|
| February 14, 2023 |
SC 13G/A 1 brhc10047998sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Quantum-Si Inc. (Name of Issuer) Class A common stock, par value $0.0001 per share (Title of Class of Securities) 74765K105 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement |
|
| February 10, 2023 |
QSI / Quantum-Si Incorporated Class A / ARK Investment Management LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| February 3, 2023 |
QSI / Quantum-Si Incorporated Class A / BlackRock Inc. Passive Investment us74765k1051020323.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) Quantum-Si Inc - (Name of Issuer) Common Stock - (Title of Class of Securities) 74765K105 - (CUSIP Number) December 31, 2022 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whic |
|
| January 30, 2023 |
Costs Associated with Exit or Disposal Activities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2023 QUANTUM-SI INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-39486 85-1388175 (State or other jurisdiction of incorporation) (Commissio |
|
| January 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2023 QUANTUM-SI INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-39486 85-1388175 (State or other jurisdiction of incorporation) (Commissio |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 QUANTUM-SI INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-39486 85-1388175 (State or other jurisdiction of incorporation) (Commission |
|
| January 9, 2023 |
Exhibit 99.1 Quantum-Si Begins Commercial Shipments of the PlatinumTM Protein Sequencing System and Provides Business Updates at the 41st Annual J.P. Morgan Healthcare Conference Company Announces Commercial Shipments of Protein Sequencing System, Reveals New Partnerships, and Reaffirms Commitment to Financial Discipline Launched in December 2022, Platinum is the First Commercially-Available Next- |
|
| December 20, 2022 |
Exhibit 99.1 Quantum-Si Announces Commercial Availability of PlatinumTM, the World?s First Next-Generation Single-Molecule Protein Sequencing Platform Quantum-Si combines Time Domain Sequencing? and Semiconductor Chip Technology to Advance Drug Discovery and Diagnostics and Accelerate Scientific Breakthroughs, Helping People to Live Healthier and Longer Lives Company Appoints Life Science Veteran |
|
| December 20, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2022 QUANTUM-SI INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-39486 85-1388175 (State or other jurisdiction of incorporation) (Commissi |
|
| November 10, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Quantum-Si Incorporated (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Class A common stock, par value $0. |
|
| November 10, 2022 |
Quantum-Si Incorporated Non-Qualified Stock Option Grant Notice Exhibit 99.1 Option No. Quantum-Si Incorporated Non-Qualified Stock Option Grant Notice 1. Name and Address of Participant: 2. Date of Option Grant: 3. Maximum Number of Shares for which this Option is exercisable: 4. Exercise (purchase) price per share: $ 5. Option Expiration Date: 6. Vesting Start Date: 7. Vesting Schedule: This Option shall become exercisable (and the Shares issued upon exercis |
|
| November 10, 2022 |
As filed with the Securities and Exchange Commission on November 10, 2022 As filed with the Securities and Exchange Commission on November 10, 2022 Registration No. |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39486 QUANT |
|
| November 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2022 QUANTUM-SI INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-39486 85-1388175 (State or other jurisdiction of incorporation) (Commissio |
|
| November 7, 2022 |
Quantum-Si Reports Third Quarter 2022 Financial Results Exhibit 99.1 Quantum-Si Reports Third Quarter 2022 Financial Results GUILFORD, Conn. - (BUSINESS WIRE) - Nov. 07, 2022 - Quantum-Si Incorporated (Nasdaq: QSI) (?Quantum-Si,? ?QSI? or the ?Company?), a life sciences company commercializing the first next-generation, single-molecule protein sequencing platform, today announced financial results for the third quarter ending September 30, 2022. Recent |
|
| October 4, 2022 |
Exhibit 99.1 Quantum-Si Appoints Jeff Hawkins as Chief Executive Officer Veteran Life Sciences Executive to Oversee Commercial Launch of Next-Generation Single-Molecule Protein Sequencing Platform GUILFORD, Conn. - (BUSINESS WIRE) - Oct. 4, 2022 - Quantum-Si Incorporated (Nasdaq: QSI) (?Quantum-Si,? ?QSI? or the ?Company?), a life sciences company commercializing the first next-generation single-m |
|
| October 4, 2022 |
Exhibit 10.1 October 2, 2022 Jeffrey Hawkins Dear Jeffrey: On behalf of Quantum-Si, I am pleased to offer you the position as Chief Executive Officer beginning no later than October 17, 2022 (your ?Start Date?). You will report to the Quantum-Si Board of Directors. Your annualized compensation in this position will consist of an annual base salary of $575,000 paid in twice monthly pay periods, les |
|
| October 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2022 QUANTUM-SI INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-39486 85-1388175 (State or other jurisdiction of incorporation) (Commission |
|
| August 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39486 QUANTUM-SI |
|
| August 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2022 QUANTUM-SI INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-39486 85-1388175 (State or other jurisdiction of incorporation) (Commission |
|
| August 8, 2022 |
Quantum-Si Reports Second Quarter 2022 Financial Results Exhibit 99.1 Quantum-Si Reports Second Quarter 2022 Financial Results GUILFORD, Conn. - (BUSINESS WIRE) ? Aug. 08, 2022 - Quantum-Si Incorporated (Nasdaq: QSI) (?Quantum-Si,? ?QSI? or the ?Company?), a life sciences company commercializing the first next-generation, single-molecule protein sequencing platform, today announced financial results for the second quarter ending June 30, 2022. Recent Bu |
|
| July 20, 2022 |
TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(3) Registration No. 333-257676 333-263514 PROSPECTUS ? QUANTUM-SI INCORPORATED Up to 72,558,225 Shares of Class A Common Stock Up to 19,937,500 Shares of Class B Common Stock Up to 135,000 Warrants This prospectus relates to the issuance by us of up to an aggregate of 3,968,319 shares of our Class A common stock, par value $0.0001 per share (?Class A |
|
| July 20, 2022 |
TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(3) Registration No. 333-257676 333-263514 PROSPECTUS ? QUANTUM-SI INCORPORATED Up to 72,558,225 Shares of Class A Common Stock Up to 19,937,500 Shares of Class B Common Stock Up to 135,000 Warrants This prospectus relates to the issuance by us of up to an aggregate of 3,968,319 shares of our Class A common stock, par value $0.0001 per share (?Class A |
|
| July 15, 2022 |
As filed with the U.S. Securities and Exchange Commission on July 15, 2022 TABLE OF CONTENTS As filed with the U.S. Securities and Exchange Commission on July 15, 2022 Registration No. 333-257676 333-263514 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 2 to FORM S-1 ON FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Quantum-Si Incorporated (Exact name of registrant as specified in its charter) Delawa |
|
| July 15, 2022 |
As filed with the U.S. Securities and Exchange Commission on July 15, 2022 TABLE OF CONTENTS As filed with the U.S. Securities and Exchange Commission on July 15, 2022 Registration No. 333-257676 333-263514 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 2 to FORM S-1 ON FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Quantum-Si Incorporated (Exact name of registrant as specified in its charter) Delawa |
|
| June 28, 2022 |
CUSIP NO. 74765K105 13D Page 1 of 17 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (RULE 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 1)* Quantum-Si Incorporated (Name of Issuer) Class A Common Stock (Title of Class of Securities) 74765K105 (CUSIP Number) Dennis Ryan |
|
| June 16, 2022 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-257676 333-263514 PROSPECTUS SUPPLEMENT NO. 6 To Prospectus dated March 3, 2022 QUANTUM-SI INCORPORATED Up to 78,841,853 Shares of Class A Common Stock Up to 19,937,500 Shares of Class B Common Stock Up to 135,000 Warrants This prospectus supplement no. 6 supplements the prospectus dated March 3, 2022 (the ?Prospectus?) relating to the issuance |
|
| June 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2022 QUANTUM-SI INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-39486 85-1388175 (State or other jurisdiction of incorporation) (Commission F |
|
| June 16, 2022 |
Quantum-Si Appoints Vikram Bajaj, Ph.D., to Board of Directors Exhibit 99.1 Quantum-Si Appoints Vikram Bajaj, Ph.D., to Board of Directors GUILFORD, Conn. - (BUSINESS WIRE) - Jun. 16, 2022 - Quantum-Si Incorporated (Nasdaq: QSI) (?Quantum-Si,? ?QSI? or the ?Company?), a life sciences company commercializing single molecule protein sequencing, today announced the appointment of Vikram Bajaj, Ph.D., co-founder and former Chief Scientific Officer of Verily (form |
|
| June 16, 2022 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-257676 333-263514 PROSPECTUS SUPPLEMENT NO. 6 To Prospectus dated March 3, 2022 QUANTUM-SI INCORPORATED Up to 78,841,853 Shares of Class A Common Stock Up to 19,937,500 Shares of Class B Common Stock Up to 135,000 Warrants This prospectus supplement no. 6 supplements the prospectus dated March 3, 2022 (the ?Prospectus?) relating to the issuance |
|
| June 10, 2022 |
Exhibit 10.1 June 10, 2022 Matthew Dyer Re: Separation Agreement Dear Matt: The purpose of this letter agreement (this ?Agreement?) is to confirm your resignation from Quantum-Si Incorporated (the ?Company?) as its Chief Business Officer as of June 15, 2022, and to set forth the terms of your separation from Quantum-Si Incorporated (?Company?). Payment of the Separation Benefits described below is |
|
| June 10, 2022 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-257676 333-263514 PROSPECTUS SUPPLEMENT NO. 5 To Prospectus dated March 3, 2022 QUANTUM-SI INCORPORATED Up to 78,841,853 Shares of Class A Common Stock Up to 19,937,500 Shares of Class B Common Stock Up to 135,000 Warrants This prospectus supplement no. 5 supplements the prospectus dated March 3, 2022 (the ?Prospectus?) relating to the issuance |
|
| June 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2022 QUANTUM-SI INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-39486 85-1388175 (State or other jurisdiction of incorporation) (Commission Fi |
|
| June 10, 2022 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-257676 333-263514 PROSPECTUS SUPPLEMENT NO. 5 To Prospectus dated March 3, 2022 QUANTUM-SI INCORPORATED Up to 78,841,853 Shares of Class A Common Stock Up to 19,937,500 Shares of Class B Common Stock Up to 135,000 Warrants This prospectus supplement no. 5 supplements the prospectus dated March 3, 2022 (the ?Prospectus?) relating to the issuance |
|
| May 16, 2022 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-257676 333-263514 PROSPECTUS SUPPLEMENT NO. 4 To Prospectus dated March 3, 2022 QUANTUM-SI INCORPORATED Up to 78,841,853 Shares of Class A Common Stock Up to 19,937,500 Shares of Class B Common Stock Up to 135,000 Warrants This prospectus supplement no. 4 supplements the prospectus dated March 3, 2022 (the ?Prospectus?) relating to the issuance |
|
| May 16, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2022 QUANTUM-SI INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-39486 85-1388175 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 16, 2022 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-257676 333-263514 PROSPECTUS SUPPLEMENT NO. 4 To Prospectus dated March 3, 2022 QUANTUM-SI INCORPORATED Up to 78,841,853 Shares of Class A Common Stock Up to 19,937,500 Shares of Class B Common Stock Up to 135,000 Warrants This prospectus supplement no. 4 supplements the prospectus dated March 3, 2022 (the ?Prospectus?) relating to the issuance |
|
| May 10, 2022 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-257676 333-263514 PROSPECTUS SUPPLEMENT NO. 3 To Prospectus dated March 3, 2022 QUANTUM-SI INCORPORATED Up to 78,841,853 Shares of Class A Common Stock Up to 19,937,500 Shares of Class B Common Stock Up to 135,000 Warrants This prospectus supplement no. 3 supplements the prospectus dated March 3, 2022 (the ?Prospectus?) relating to the issuance |
|
| May 10, 2022 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-257676 333-263514 PROSPECTUS SUPPLEMENT NO. 3 To Prospectus dated March 3, 2022 QUANTUM-SI INCORPORATED Up to 78,841,853 Shares of Class A Common Stock Up to 19,937,500 Shares of Class B Common Stock Up to 135,000 Warrants This prospectus supplement no. 3 supplements the prospectus dated March 3, 2022 (the ?Prospectus?) relating to the issuance |
|
| May 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39486 QUANTUM-S |
|
| May 9, 2022 |
Quantum-Si Reports First Quarter 2022 Financial Results Exhibit 99.1 Quantum-Si Reports First Quarter 2022 Financial Results GUILFORD, Conn. - (BUSINESS WIRE) ? May 09, 2022 - Quantum-Si Incorporated (Nasdaq: QSI) (?Quantum-Si,? ?QSI? or the ?Company?), a life sciences company commercializing single molecule protein sequencing, today announced financial results for the first quarter ending March 31, 2022. Recent Business Highlights ? Announced the appo |
|
| May 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2022 QUANTUM-SI INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-39486 85-1388175 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 9, 2022 |
Quantum-Si Appoints Patrick Schneider as President and Chief Operating Officer Exhibit 99.2 Quantum-Si Appoints Patrick Schneider as President and Chief Operating Officer GUILFORD, Conn.?(BUSINESS WIRE)-May 09, 2022- Quantum-Si Incorporated (Nasdaq: QSI) (?Quantum-Si,? ?QSI? or the ?Company?), a life sciences company commercializing single molecule protein sequencing, today announced the appointment of Patrick Schneider, Ph.D., as President and Chief Operating Officer (COO). |
|
| May 9, 2022 |
Exhibit 10.1 April 26, 2022 Patrick Schneider Dear Patrick: On behalf of Quantum-Si, I am pleased to offer you the position as President and Chief Operating Officer beginning no later than June 1, 2022. You will report to the Quantum-Si CEO. Your annualized compensation in this position will consist of an annual base salary of $475,000 paid in twice monthly pay periods, less required deductions. B |
